Vyfemla

Endometriosis, Low Testosterone, Osteoporosis + 16 more

Treatment

20 Active Studies for Vyfemla

What is Vyfemla

Norethisterone

The Generic name of this drug

Treatment Summary

Norethisterone, also known as norethindrone, is a synthetic hormone used to treat menstrual irregularities, endometriosis, and other conditions. It is a second-generation progestin, meaning it is a more potent form of progesterone. Norethisterone was first developed in 1951, and was initially used to treat menstrual problems. In 1962, it was approved for use as an oral contraceptive.

Necon

is the brand name

Vyfemla Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Necon

Norethisterone

1967

347

Effectiveness

How Vyfemla Affects Patients

Norethisterone is a synthetic hormone pill used as a form of birth control or to treat other hormone-related conditions such as menopause and endometriosis. It is much stronger than the hormone progesterone that is naturally produced in the body. Norethisterone works to change the function of the cervix and uterus, as well as how the pituitary gland makes hormones that control ovulation. There is evidence that taking this pill may slightly increase the risk of developing breast cancer, so it is important to be aware of this risk and to do regular self-examinations for any changes or masses

How Vyfemla works in the body

Norethisterone works by binding to progesterone receptors in different parts of the body, like the reproductive tract, breast, pituitary, hypothalamus, skeletal tissue and central nervous system. It thickens cervical mucus to prevent sperm from entering the uterus, and makes the endometrium inhospitable for implantation. It also works to suppress the release of hormones that cause follicles to grow and ovulation to occur. When used for hormone replacement therapy in menopausal women, it helps prevent endometrial hyperplasia, which can increase the risk of endometrial cancer. Norethisterone has a

When to interrupt dosage

The dosage of Vyfemla is contingent upon the identified ailment, including Atrophic, Fracture and Hormone Replacement Therapy. The measure of dosage changes as per the delivery approach (e.g. Oral or Tablet) mentioned in the table below.

Condition

Dosage

Administration

Fracture

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule, Capsule - Oral, Intramuscular; Oral; Topical

Osteoporosis

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule, Capsule - Oral, Intramuscular; Oral; Topical

Atrophic

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule, Capsule - Oral, Intramuscular; Oral; Topical

hypoestrogenism

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule, Capsule - Oral, Intramuscular; Oral; Topical

Hot flashes

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule, Capsule - Oral, Intramuscular; Oral; Topical

Birth Control

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule, Capsule - Oral, Intramuscular; Oral; Topical

Therapeutic procedure

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule, Capsule - Oral, Intramuscular; Oral; Topical

Endometriosis

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule, Capsule - Oral, Intramuscular; Oral; Topical

Menopause

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule, Capsule - Oral, Intramuscular; Oral; Topical

Estrogen Deprivation Symptoms

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule, Capsule - Oral, Intramuscular; Oral; Topical

Oral Contraceptives

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule, Capsule - Oral, Intramuscular; Oral; Topical

Low Testosterone

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule, Capsule - Oral, Intramuscular; Oral; Topical

Osteoporosis, Postmenopausal

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule, Capsule - Oral, Intramuscular; Oral; Topical

Endometriosis

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule, Capsule - Oral, Intramuscular; Oral; Topical

Primary Ovarian Insufficiency

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule, Capsule - Oral, Intramuscular; Oral; Topical

Hormonal Contraception

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule, Capsule - Oral, Intramuscular; Oral; Topical

female castration

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule, Capsule - Oral, Intramuscular; Oral; Topical

Hormone Replacement Therapy

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule, Capsule - Oral, Intramuscular; Oral; Topical

Vasomotor System

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule, Capsule - Oral, Intramuscular; Oral; Topical

Warnings

Vyfemla Contraindications

Condition

Risk Level

Notes

Liver Diseases

Do Not Combine

Thrombophilia

Do Not Combine

Vaginal Hemorrhage

Do Not Combine

Malignant Neoplasms

Do Not Combine

Benign hepatic neoplasm

Do Not Combine

Breast Cancer

Do Not Combine

Thromboembolism

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Norethisterone may interact with Pulse Frequency

There are 20 known major drug interactions with Vyfemla.

Common Vyfemla Drug Interactions

Drug Name

Risk Level

Description

Astemizole

Major

The metabolism of Astemizole can be decreased when combined with Norethisterone.

Axitinib

Major

The metabolism of Axitinib can be decreased when combined with Norethisterone.

Cabazitaxel

Major

The metabolism of Cabazitaxel can be decreased when combined with Norethisterone.

Clomipramine

Major

The metabolism of Clomipramine can be increased when combined with Norethisterone.

Copanlisib

Major

The metabolism of Copanlisib can be decreased when combined with Norethisterone.

Vyfemla Toxicity & Overdose Risk

The lowest toxic dose of oral contraceptives in mice is 6g/kg, and in women is 42mg/kg. No serious health issues have been reported from taking too many oral contraceptives, even among children. Overdosing on oral contraceptives may cause severe nausea and vomiting.

image of a doctor in a lab doing drug, clinical research

Vyfemla Novel Uses: Which Conditions Have a Clinical Trial Featuring Vyfemla?

160 active studies are presently assessing the potential of Vyfemla to ameliorate Birth Control, Atrophic changes and Low Testosterone levels.

Condition

Clinical Trials

Trial Phases

Birth Control

19 Actively Recruiting

Not Applicable, Phase 3, Phase 4, Early Phase 1, Phase 2

Oral Contraceptives

1 Actively Recruiting

Not Applicable

Endometriosis

30 Actively Recruiting

Early Phase 1, Phase 2, Not Applicable, Phase 3, Phase 4

Osteoporosis

28 Actively Recruiting

Not Applicable, Phase 4, Phase 1, Phase 3, Phase 2

Low Testosterone

5 Actively Recruiting

Phase 4, Phase 2, Phase 1

Endometriosis

2 Actively Recruiting

Phase 4, Not Applicable

Hot flashes

19 Actively Recruiting

Not Applicable, Phase 2, Phase 4, Early Phase 1, Phase 3

Estrogen Deprivation Symptoms

0 Actively Recruiting

Osteoporosis, Postmenopausal

0 Actively Recruiting

female castration

0 Actively Recruiting

Atrophic

5 Actively Recruiting

Phase 4, Not Applicable

Hormone Replacement Therapy

0 Actively Recruiting

Hormonal Contraception

0 Actively Recruiting

hypoestrogenism

1 Actively Recruiting

Phase 4

Fracture

0 Actively Recruiting

Vasomotor System

0 Actively Recruiting

Primary Ovarian Insufficiency

0 Actively Recruiting

Therapeutic procedure

0 Actively Recruiting

Menopause

0 Actively Recruiting

Vyfemla Reviews: What are patients saying about Vyfemla?

5

Patient Review

8/9/2017

Vyfemla for Abnormally Long or Heavy Periods

I've been on this medication for a year and it has helped to regulate my cycles. They were irregular before, but now they are much lighter. I don't even bleed; I only spot occasionally.

4.7

Patient Review

3/18/2019

Vyfemla for Abnormally Long or Heavy Periods

I switched to this brand of birth control about six months ago to help with my acne and cramping. My acne is much better, though the cramps are still an issue. I have gained some weight, but in my opinion, it's worth it!

4

Patient Review

8/2/2016

Vyfemla for Birth Control

4

Patient Review

8/2/2016

Vyfemla for Abnormally Long or Heavy Periods

This medication was very effective in stopping my abnormal bleeding. However, the side effects were brutal. I experienced severe chest pain and difficulty breathing to the point of not being able to get out of bed for days at a time.

3.7

Patient Review

1/9/2020

Vyfemla for Acne

I experienced some major cramping and breakthrough bleeding while on this medication. It would happen if I had sex, and it was like period bleeding. However, it did clear up my skin.

3.3

Patient Review

8/9/2020

Vyfemla for Birth Control

I've only been on this pill for a week, and I've already experienced some serious side effects like mood swings, vomiting, and spotting. I'm going to give it a month to see if my body gets used to it, but so far I'm not impressed.

Patient Q&A Section about vyfemla

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Vyfemla generic for?

"Vyfemla is a drug taken orally that is indicated for preventing pregnancy. It is available in generic form."

Answered by AI

Is Azurette progestin only?

"This medication contains two hormones: a progestin (desogestrel) and an estrogen (ethinyl estradiol)."

Answered by AI

Does Vyfemla cause weight gain?

"The most commonly reported side effects were headaches, vaginal candidiasis, nausea, menstrual cramps, breast tenderness, abdominal pain, mood changes, bacterial vaginitis, acne, irregular uterine bleeding, and weight gain."

Answered by AI

What is Yaz called now?

"There are two birth control pills on the market today, Yaz and Loryna. Loryna is a generic version of Yaz."

Answered by AI

Clinical Trials for Vyfemla

Image of VA Greater Los Angeles Healthcare System, West Los Angeles, CA in West Los Angeles, United States.

EBQI Strategies for Women's Health

Any Age
All Sexes
West Los Angeles, CA

Women Veterans are the fastest growing segment of VA users, with most users in midlife. This dramatic growth has created challenges for VA to ensure that appropriate services are available to meet women Veterans' needs, and that they will want and be able to use those services. Furthermore, few VA improvement efforts have focused on women Veterans' health and health care in midlife. The EMPOWER QUERI 3.0 Program is a cluster randomized type 3 hybrid implementation-effectiveness trial testing two strategies designed to support implementation and sustainment of evidence-based practices for women Veterans in at least 18 VA facilities from 4 regions.

Waitlist Available
Has No Placebo

VA Greater Los Angeles Healthcare System, West Los Angeles, CA

Erin P Finley, PhD MPH

Image of UC San Diego in San Diego, United States.

Epione Device for Bone Conditions

18+
All Sexes
San Diego, CA

The goal of this investigational device exemption is to evaluate the Epione assistance for introducer placement during percutaneous procedures in musculo-skeletic (MSK) structures of the pelvis and the spine in adults. The main question is the determination of the rate of feasible procedures assisted by the Epione device Participants will undergo their procedure(s) as planned by their physician. If they accept to participate to the study, the differences with standard of care will be: * The use of the Epione device to place the introducer(s), instead of freehand placement if they do not participate * Additional CT or CBCT scans during the procedure.

Waitlist Available
Has No Placebo

UC San Diego (+2 Sites)

Sean Tutton, MD

Quantum Surgical

Image of University of Waterloo in Waterloo, Canada.

Virtual Chiropractic Intervention for Spinal Fracture

18+
All Sexes
Waterloo, Canada

This study will determine feasibility of a chiropractor delivered virtual intervention for individuals following osteoporotic vertebral fracture. This pilot trial will have two parallel groups with a 1:1 ratio. Participants will be randomized to: 1) immediate receipt; or 2) waitlist usual care control and delayed receipt of VIVA 10 weeks post-randomization. VIVA is an intervention for people with vertebral fractures that covers four areas: pain management, safe movement, exercise, and nutrition. It includes print and video resources, and a framework for goal setting, selecting exercises, and teaching body mechanics. A chiropractor (DC) completes a virtual assessment and then leads twelve 1:1 virtual sessions (via Zoom) over eight weeks. Sessions start with brief education on a topic (e.g., safe movement, pain management, exercise, nutrition), followed by training and modeling of exercise and safe movement strategies, then goal setting, and action planning. This trial will be considered feasible if a) we recruit 14 people in eight months; b) 80% of participants complete the trial; and c) exercise adherence is 75%.

Recruiting
Has No Placebo

University of Waterloo

Have you considered Vyfemla clinical trials?

We made a collection of clinical trials featuring Vyfemla, we think they might fit your search criteria.
Go to Trials
Image of Erevna Innovations Inc. in Montreal, Canada.

Sculptra + Restylane for Post-Menopausal Skin Concerns

40 - 65
Female
Montreal, Canada

The post-menopausal state is marked by a sharp decline in estrogen, leading to significant structural and functional changes in the skin, including collagen loss, dryness, thinning, and reduced elasticity. To address these concerns, aesthetic injectables products such as Sculptra® Aesthetic (poly-L-lactic-acid \[PLLA- SCA\]) and Restylane Skinboosters®\[HASBV\] (small-particle hyaluronic acid - SP-HA) can be used. PLLA-SCA stimulates collagen production via cellular activation (biostimulator), gradually improving dermal structure. HASBV enhances hydration, elasticity, and skin texture when injected under the skin. Considering that hydration and laxity represent the primary aesthetic concerns in this patient population. Targeted treatment with SP-HA (HASBV) to improve hydration and PLLA-SCA to address laxity have been shown to produce significant clinical outcomes by directly addressing these key dermal deficiencies. This approach forms the basis of the current study.

Phase 4
Recruiting

Erevna Innovations Inc.

Andreas Nikolis, MD, PhD

Image of University Hospitals Cleveland Medical Center in Cleveland, United States.

Ketamine for Pelvic Pain

18 - 89
Female
Cleveland, OH

The purpose of this research study is to see if ketamine infusion during surgery can decrease pain after surgery. Ketamine is a medication commonly used as part of anesthesia during surgery and is approved by the US FDA. Patients will be randomized to either receive standard anesthesia with OR without ketamine. The surgical procedure will be the same regardless of which group patients are randomized to. After surgery, patients will be asked to rate their pain in the post-operative observation unit and at their two-week post-operative visit. No additional visits are required for participation in this study. The investigators estimate the surveys will take approximately 10 minutes to complete.

Phase 4
Waitlist Available

University Hospitals Cleveland Medical Center

Morgan Cheeks, MD

Have you considered Vyfemla clinical trials?

We made a collection of clinical trials featuring Vyfemla, we think they might fit your search criteria.
Go to Trials

Have you considered Vyfemla clinical trials?

We made a collection of clinical trials featuring Vyfemla, we think they might fit your search criteria.
Go to Trials